Connaught Bio-targeted MASP-2 innovative antibody CM338 was approved for clinical use

ArticleMedicine Guanlan

On November 1, Connoa Biosciences announced that the company's self-developed MASP-2 innovative monoclonal antibody drug CM338 has obtained clinical trial approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration

CM338 targets a new pro-inflammatory protein target, MASP-2

Studies have shown that the activation of the lectin pathway is through mannose-binding lectin that recognizes a variety of pathogen-related target molecules and then binds to MASP-2 to activate the complement cascade, of which MASP-2 is the key rate-limiting enzyme

Preclinical studies have shown that CM338 has a clear mechanism of action, obvious in vivo and in vitro drug effects, and at the same time has a high affinity and in vitro inhibitory activity, up to 30 times

According to the CDE clinical trial implied permission announcement, this time CM338 was approved for clinical use, and it is planned to be developed for IgA nephropathy

Studies have shown that 90% of patients with IgA nephropathy have C3 and IgA co-localization, and C3 and C4 are often detected as complement deposits, which are closely related to renal tissue pathological damage and local inflammation

Reference materials:

[1] The first domestic innovative monoclonal antibody drug CM338 independently developed by Connoa was approved for clinical use.